Literature DB >> 3513613

Insulin resistance in acromegaly: defects in both hepatic and extrahepatic insulin action.

I Hansen, E Tsalikian, B Beaufrere, J Gerich, M Haymond, R Rizza.   

Abstract

Short-term growth hormone excess is associated with impaired hepatic and extrahepatic responses to insulin in the absence of a change in insulin binding. To determine whether similar defects occur after chronic growth hormone excess, insulin dose-response curves for stimulation of glucose utilization and suppression of glucose production and monocyte and erythrocyte insulin binding were determined in five acromegalic patients and six healthy volunteers of comparable age, sex, and obesity. During infusion of insulin, glucose infusion rates required to maintain euglycemia were significantly lower (P less than 0.02 all) in the acromegalic patients than in the control subjects. Suppression of glucose production was impaired in the acromegalic subjects at insulin concentrations in the physiological range but not at insulin concentrations in the supraphysiological range. In contrast stimulation of glucose utilization was decreased in the acromegalic subjects at both physiological and supraphysiological insulin concentrations. Neither monocyte nor erythrocyte insulin binding differed significantly in the acromegalic and control subjects. These data indicate that chronic growth hormone excess is associated with a defect in both hepatic and extrahepatic insulin action. The decrease in glucose utilization at supraphysiological insulin concentrations in the acromegalic subjects and the normal monocyte and erythrocyte insulin binding suggest a postbinding alteration in insulin action.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3513613     DOI: 10.1152/ajpendo.1986.250.3.E269

Source DB:  PubMed          Journal:  Am J Physiol        ISSN: 0002-9513


  40 in total

Review 1.  Regulation of adipocytokines and insulin resistance.

Authors:  M Fasshauer; R Paschke
Journal:  Diabetologia       Date:  2003-11-06       Impact factor: 10.122

Review 2.  Therapy of diabetes and dyslipidemia in acromegaly.

Authors:  G Tamburrano; C Durante; R Baldelli
Journal:  Pituitary       Date:  2002-01       Impact factor: 4.107

Review 3.  Role of the GH/IGF-1 axis in lifespan and healthspan: lessons from animal models.

Authors:  Darlene E Berryman; Jens Sandahl Christiansen; Gudmundur Johannsson; Michael O Thorner; John J Kopchick
Journal:  Growth Horm IGF Res       Date:  2008-08-16       Impact factor: 2.372

4.  IGF-1 levels across the spectrum of normal to elevated in acromegaly: relationship to insulin sensitivity, markers of cardiovascular risk and body composition.

Authors:  Tirissa J Reid; Zhezhen Jin; Wei Shen; Carlos M Reyes-Vidal; Jean Carlos Fernandez; Jeffrey N Bruce; Jane Kostadinov; Kalmon D Post; Pamela U Freda
Journal:  Pituitary       Date:  2015-12       Impact factor: 4.107

5.  Growth hormone controls lipolysis by regulation of FSP27 expression.

Authors:  Rita Sharma; Quyen Luong; Vishva M Sharma; Mitchell Harberson; Brian Harper; Andrew Colborn; Darlene E Berryman; Niels Jessen; Jens Otto Lunde Jørgensen; John J Kopchick; Vishwajeet Puri; Kevin Y Lee
Journal:  J Endocrinol       Date:  2018-12-01       Impact factor: 4.286

6.  Identification of Main Factors Explaining Glucose Dynamics During and Immediately After Moderate Exercise in Patients With Type 1 Diabetes.

Authors:  Najib Ben Brahim; Jerome Place; Eric Renard; Marc D Breton
Journal:  J Diabetes Sci Technol       Date:  2015-10-18

7.  Central ghrelin regulates peripheral lipid metabolism in a growth hormone-independent fashion.

Authors:  Susana Sangiao-Alvarellos; María J Vázquez; Luis Varela; Rubén Nogueiras; Asish K Saha; Fernando Cordido; Miguel López; Carlos Diéguez
Journal:  Endocrinology       Date:  2009-07-16       Impact factor: 4.736

8.  Lower visceral and subcutaneous but higher intermuscular adipose tissue depots in patients with growth hormone and insulin-like growth factor I excess due to acromegaly.

Authors:  Pamela U Freda; Wei Shen; Steven B Heymsfield; Carlos M Reyes-Vidal; Eliza B Geer; Jeffrey N Bruce; Dympna Gallagher
Journal:  J Clin Endocrinol Metab       Date:  2008-03-18       Impact factor: 5.958

9.  Skeletal muscle glucose transporter gene expression is not affected by injecting growth-hormone-secreting cells in young rats.

Authors:  H Imamura; I Morimoto; S Etoh; T Usa; H Namba; A Ohtsuru; A Yokota; S Nagataki; S Yamashita
Journal:  Diabetologia       Date:  1993-06       Impact factor: 10.122

10.  Therapeutic options in the management of acromegaly: focus on lanreotide Autogel.

Authors:  Ferdinand Roelfsema; Nienke R Biermasz; Alberto M Pereira; Johannes A Romijn
Journal:  Biologics       Date:  2008-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.